Since cDC1s are usually very sparse within the tumor, therapies aimed at increasing intratumoral cDC1 abundance are expected to boost anti-tumor immunity and potentially increase the responsiveness of cancer patients to immunotherapy inhibiting tumor-derived immunosuppression [21, 22]. The gene discussed is MPPE1; the disease is neoplasm.